相关期刊:《World Journal of Clinical Cases》《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》《Journal of Geriatric Cardiology》《Chinese Journal of Traumatology》更多>>
supported by the Chinese PLA Special Research on Health Care (17BJZ08)
BACKGROUND Uninterrupted use of oral anticoagulants before atrial fibrillation(AF)ablation can reduce the incidence of perioperative thromboembolic events.However,the effect of new oral anticoagulants on activated clo...
BACKGROUND The drug instructions for dabigatran recommend adjusting the dosage to 110 mg twice daily for patients with bleeding risk,and performing at least one renal function test per year for patients with moderate ...
Dabigatran,a direct thrombin inhibitor,has robust data for the treatment of deep venous thrombosis and pulmonary embolism,stroke prevention in non-valvular atrial fibrillation,and the prophylaxis of venous thromboembo...
BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation(AF)originated from western countrie...
One disadvantage of direct anticoagulant drug is the lack of an antidote, which may become relevant in patients with traumatic brain in- jury. A 77-years old man with atrial fibrillation and syncope received dabigatra...
Project (No. 200902001) supported by the Research on Monitoring,Prevention, Early-Warning, Diagnosis,and Therapy of Cardiovascular Diseases Part Ⅱ:Community Based Approach for Atrial Fibrillation and Sudden Cardiac Death, China
Atrial fibrillation (AF) increases the risk of stroke. New anticoagulation agents have recently provided alternative and promising approaches. This paper reviews the current state of anticoagulation therapy in AF pati...